ArticleInternational journal of women's health2025
The Treatment of Fetal Supraventricular Tachycardia: A Case Report and Literature Review.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Evaluation of Neonatal Arrhythmias: Experience from a Specialized Pediatric Cardiac Center.Journal of cardiovascular development and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fetal supraventricular tachycardia (SVT), as the most common fetal tachyarrhythmia, can lead to serious complications such as decreased cardiac output, ascites, pleural or pericardial effusion, skin edema, and even fetal hydrops in specific cases, marking the severe stage of fetal congestive heart failure. Hydrops significantly increases infant mortality. Therefore, timely treatment and restoration of normal fetal heart rate are essential for fetal survival and full-term delivery. Based on clinical cases, this article discusses the current situation of fetal SVT treatment and individual differences, as well as the strategy of fetal drug conservative treatment and the best time to terminate pregnancy. Here we report a case of supraventricular tachycardia diagnosed by fetal heart rate monitoring at 29 weeks and 2 days of gestation. The results of fetal heart ultrasound and Doppler monitoring showed that the fetus had the possibility of cardiac insufficiency and fetal intracranial hydrops, and the fetal heart rate returned to normal after oral treatment with digoxin and sotalol. The pregnancy was terminated by cesarean section at 36 weeks and 5 days of gestation because of recurrent supraventricular tachycardia, reverse a wave of venous catheter and oligohydramnios. The newborn weighed 3035 grams. No arrhythmia was found in the follow-up of pregnant women and newborns. Fetal supraventricular tachycardia does not necessarily terminate pregnancy. In fact, most of these fetuses have a good prognosis after conservative treatment in utero. The treatment plan should take into account the gestational age, the specific conditions of the fetus and the mother. The purpose of this article is to review the diagnosis and treatment process of this case and provide valuable reference for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.